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Abstract
Asthma and rhinitis are often co-morbid conditions. As rhinitis often precedes asthma it is possible
that effective treatment of allergic rhinitis may reduce asthma progression.
The aim of our study is to investigate history of allergic rhinitis as a risk factor for asthma and the
potential effect of allergen immunotherapy in attenuating the incidence of asthma.
Hospital-referred non-asthmatic adults, aged 18–40 years between 1990 and 1991, were
retrospectively followed up until January and April 2000. At the end of follow up, available subjects
were clinically examined for asthma diagnosis and history of allergen specific immunotherapy,
second-hand smoking and the presence of pets in the household. A total of 436 non-asthmatic
adults (332 subjects with allergic rhinitis and 104 with no allergic rhinitis nor history of atopy) were
available for final analyses.
The highest OR (odds ratio) associated with a diagnosis of asthma at the end of follow-up was for
the diagnosis of allergic rhinitis at baseline (OR, 7.8; 95%CI, 3.1–20.0 in the model containing the
covariates of rhinitis diagnosis, sex, second-hand smoke exposure, presence of pets at home, family
history of allergic disorders, sensitization to Parietaria judaica; grass pollen; house dust mites; Olea
europea: orchard; perennial rye; and cat allergens). Female sex, sensitization to Parietaria judaica and
the presence of pets in the home were also significantly predictive of new onset asthma in the same
model. Treatment with allergen immunotherapy was significantly and inversely related to the
development of new onset asthma (OR, 0.53; 95%CI, 0.32–0.86).
In the present study we found that allergic rhinitis is an important independent risk factor for
asthma. Moreover, treatment with allergen immunotherapy lowers the risk of the development of
new asthma cases in adults with allergic rhinitis.
Published: 28 December 2005
Respiratory Research 2005, 6:153 doi:10.1186/1465-9921-6-153
Received: 06 May 2005
Accepted: 28 December 2005
This article is available from: http://respiratory-research.com/content/6/1/153
© 2005 Polosa et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Respiratory Research 2005, 6:153 http://respiratory-research.com/content/6/1/153
Page 2 of 11
(page number not for citation purposes)
Study flow diagram Figure 1
Study flow diagram. Medical records of cases who were referred in the period between January 1990 and December 1991 to 
the clinic for the diagnosis and treatment of allergic diseases were reviewed. To be included in the study cases had to be 
between the ages of 18 and 40 years and not diagnosed with asthma at the time of referral. A total of 1104 records were 
selected at baseline. In the period from January to April 2000, subjects were contacted for a follow up visit to evaluate the pos-
sibility of asthma diagnosis; 629 subjects were lost to follow-up leaving 475 subjects taking part in the study. A diagnosis of 
asthma could not be established with confidence in 39 subjects, leaving a total of 436 subjects for the final analyses. Among 
those 436 subjects, 332 had allergic rhinitis and 104 had no allergic rhinitis or history of atopy. At follow up, 46.1% (n = 153) of 
those with rhinitis at baseline developed asthma.Respiratory Research 2005, 6:153 http://respiratory-research.com/content/6/1/153
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Introduction
Asthma is one of the most common chronic conditions in
developed countries, with a prevalence that has been
increasing globally since the 1970s [1-3]. Asthma is often
associated with allergic rhinitis (AR) and the overall char-
acteristics of the diseases and treatment options for these
disorders are similar [4,5].
Several studies have suggested that AR usually precedes
asthma and that rhinitis may be an important risk factor
for the development of asthma. In a proportion of allergic
rhinitic individuals, bronchial challenge with histamine
or methacholine may reveal bronchial hyperresponsive-
ness (BHR) even in the absence of any asthmatic symp-
toms [6,7] and this may be a reflection of sub-clinical
inflammatory changes in the lower airways [8-10]. Rhi-
nitic subjects with documented BHR are known to be at
risk for asthma progression [11-13]. In addition, a
number of epidemiological surveys in adults suggest that
allergic rhinitis may be a prelude to airway symptoms
related to asthma [14-18]. However, these five studies
mostly rely on postal questionnaires for the diagnosis of
allergic rhinitis and asthma. Moreover, the possibility that
treatment modalities (especially regular nasal corticoster-
oids) might have altered the natural course of the disease
could not be excluded with confidence.
It is possible that effective treatment of allergic rhinitis
may reduce asthma progression. The efficacy of allergen-
specific immunotherapy (SIT) for allergic conditions has
been highlighted in a recent World Health Organization
report that advocates its use in selected patients [19].
Although the evidence of its effectiveness in asthma is still
controversial, its efficacy in reducing the severity of symp-
toms related to allergic rhino-conjunctivitis has been
established in randomized controlled studies [19,20]. It is
also possible that in susceptible individuals, SIT may be
effective in reducing progression to asthma rather than
reversing its course once the disease is established [21-23].
However, larger studies are needed in order to confirm
whether SIT is truly beneficial in decreasing the incidence
of asthma in subjects with AR and to define the character-
istics of patients who would benefit most from such a
therapeutic approach.
The present study was carried out with a cohort of non-
asthmatic adult subjects with and without AR to define its
importance as a risk factor for asthma during follow-up
while adjusting for known asthma risk factors. We also
wanted to investigate the potential effect of SIT treatment
among patients with AR in reducing asthma progression.
Materials and methods
Study population
The Outpatient Allergy Clinic of the University of Catania,
Sicily is the primary referral center for respiratory allergies
in the area of Catania. We reviewed the medical records of
1104 cases, with either allergic rhinitis or with no allergic
rhinitis or history of atopy, who were referred to the clinic
for the diagnosis and treatment of allergic diseases (Figure
1). To be included in the initial selection the subjects had
to be between the ages of 18 and 40 years and not diag-
nosed with asthma at the time of referral, in the period
between January 1990 and December 1991. The referred
cases had to be born and residing in the province of Cata-
nia – Sicily.
Our standardized diagnostic protocol at the time of refer-
ral consisted of case history, clinical examination, spirom-
etry, and skin tests (Figure 2). Skin prick testing was
performed on all subjects to determine sensitivity to com-
mon allergens (including Parietaria judaica, Dermatopha-
goides pteronyssinus, Dermatophagoides farinae, Olea europea,
grass pollen, orchard, cypressus, alternaria, perennial rye,
and cat allergen). We used 0.1% histamine solution as the
positive quality control of the skin prick test and used the
diluent media for allergens as the negative control. Skin
prick tests were regarded positive if the mean wheal diam-
eter was more than 3 mm. Referred patients who had no
Diagnostic procedures Figure 2
Diagnostic procedures. With the exception of skin prick 
testing – SPT, case history (paying particular attention to the 
presence of a past or present history of asthma and/or previ-
ous asthma symptoms or asthma medication intake), physical 
examination and simple spirometry were repeated at base-
line (1990–91) and follow-up visits (2000). Bronchial provo-
cation testing – BPT with inhaled methacholine were carried 
out in selected cases on both visits.Respiratory Research 2005, 6:153 http://respiratory-research.com/content/6/1/153
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diagnosis of allergic rhinitis and no positive skin prick test
were also included to assess the difference in asthma inci-
dence at the end of follow up among those with and with-
out rhinitis at the baseline. Those who were referred to the
clinic, but not diagnosed with allergic rhinitis, were
mainly referred because they wanted to be seen for
"allergy-related" symptoms, of which most were due to
drug allergy, food intolerance, chronic urticaria, post-viral
rhinorrea, and infectious/viral conjunctivitis.
The diagnostic criteria used for allergic rhinitis were those
defined by the Joint Task Force on Practice Parameters in
Allergy, Asthma and Immunology [24] and included
watery rhinorrea, nasal itch, sneezing, nasal blockage,
excessive lacrimation or conjunctival redness when
exposed to allergens, in combination with positive skin
test reactions to suspected allergens.
Records were excluded from the study if there was a past
or present history of asthma, previous asthma symptoms
or asthma medication intake, and/or abnormal spiromet-
ric values at the time of referral at baseline (Figure 2). The
possibility of unrecognised asthma in our study popula-
tion was addressed by further reviewing their case histo-
ries and subjects were eligible for inclusion in the study
only after at least two specialists in allergic diseases agreed
they did not have any clinical history or symptoms sugges-
tive of asthma. The criteria used to record a diagnosis of
asthma (the main endpoint of the study) were those based
on the ATS guidelines [25] and on the recommendations
established by the National Heart, Lung and Blood Insti-
tute of the National Institutes of Health [26].
Study design and procedures
The present study took the form of a retrospective cohort
study of allergic rhinitic and non-allergic subjects (Figure
1). The records were selected from among the 1104
referred subjects at baseline. Subjects seeking sympto-
matic relief were not excluded if they only used over the
counter drugs, such as topical decongestants, intranasal
sodium cromoglycate, and/or oral antihistamines, when
needed throughout the study follow-up. When nasal cor-
ticosteroids were prescribed, therapy had to be restricted
to no more than 6 weeks/year. None of the subjects
included had ever received allergen specific immuno-
therapy at baseline.
In the period from January to April 2000 we were able to
contact 475 subjects (258 Males; 217 Females) among the
study population selected at baseline (1990–1991). They
were invited to the Clinic for a follow up visit in order to
evaluate the possibility of asthma diagnosis [25,26] (Fig-
ure 2). All subjects reporting unclear symptoms of asthma
and with normal spirometric values at the time of clinical
follow up were also investigated by methacholine chal-
lenge [27] and further reviewed 9 months later for accu-
rate classification of asthma. The remaining 629 subjects
of the initial 1104 eligible subjects, (496 atopics [265
Males and 231 Females], and 133 non-atopics [56 Males
and 77 Females]) were lost to follow-up because they
could not be contacted as a result of extensive recoding of
the local telephone lines that occurred between 1995–
1996 (n = 485; 77.1%) or because they repeatedly failed
to attend their follow-up visit (n = 144; 22.9%).
A diagnosis of asthma could not be established with con-
fidence in 39 subjects (21 Males; 18 Females) at the end
of follow up and were therefore excluded from the study
leaving a total of 436 subjects for the final analyses.
Among those 436 subjects, 332 had allergic rhinitis and
104 had no allergic rhinitis or history of atopy. On the
same follow up occasion subjects were invited to com-
plete a questionnaire on respiratory and allergic condi-
tions (modified from the ISAAC core questions [28]),
Table 1: Frequency for each variable at baseline and distribution of covariates, at baseline and during follow up, according to diagnosis 
of asthma at the end of follow up.
Covariates Frequency (%) Asthma No-asthma Chi square P value
Presence of allergic rhinitis 332 (76.2) 95% 65% <0.0001
Female sex 199 (45.1) 57% 38% <0.0001
Positive family history for allergic disorders 274 (62.8) 71% 58% 0.0085
Presence of pets in the home 149 (34.2) 45% 28% 0.0004
Parental smoking at home 178 (40.8) 63% 57% 0.17
Sensitization to Parietaria judaica 232 (53.2) 75% 41% <0.0001
Sensitization to house dust mite 107 (24.5) 28% 23% 0.21
Sensitization to Olea europea 112 (25.7) 32% 22% 0.029
Sensitization to grass pollen 48 (11.0) 14% 10% 0.18
Sensitization to orchard 100 (22.9) 27% 20% 0.13
Sensitization to perennial rye 99 (22.7) 26% 22% 0.34
Sensitization to cat 34 (7.8) 9% 7% 0.37
Sensitization to cypressus 16 (3.7) 4% 3% 0.56
Sensitization to alternaria 18 (4.1) 4% 4% 0.75Respiratory Research 2005, 6:153 http://respiratory-research.com/content/6/1/153
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which included queries on the development of asthma
symptoms, the need for drug therapy for rhinitis and/or
asthma, in addition to questions on the family history for
atopic disease, second-hand smoke exposure history, and
pet ownership. The questionnaire also included questions
on changes in the clinical rating of rhinitic symptoms if
they during follow up.
The potential effect of allergen immunotherapy in
decreasing the incidence of asthma was evaluated only in
those subjects who had been taking allergen immuno-
therapy for at least 3 consecutive years during the follow
up period. Allergen immunotherapy is indicated in
patients with IgE-mediated disease (symptoms on expo-
sure to relevant allergen supported by a positive SPT to
that allergen) with a limited spectrum (1 or 2) of allergies
and with short disease duration [19]. Patients considered
for immunotherapy had documented positive skin sensi-
tivity to at least one allergen (class ++ or more) with the
duration of their rhinitis not exceeding 10 years. Allergen
immunotherapy consisted of a selection of commercially
available extracts of Parietaria judaica or Dermatophagoides
mix (D. pteronyssinus + farinae; house dust mites). House
dust mites and Paritaria judaica allergen extracts conju-
gated with either sodium alginate (Conjuvac; DHS-Bayer)
or alum hydroxide (Lofarma Depot Immunotherapy;
Lofarma) or tyrosine-adsorbed glutaraldehyde-modified
extract of Parietaria judaica pollen (Bencard Parietaria;
Bencard) were generally used.
Injections were administered by trained physicians
according to manufacturers' recommendations, but tai-
lored to individual patients' clinical circumstances. In
general, immunotherapy protocols involved weekly injec-
tions during an updosing phase, followed by monthly
maintenance injections for a period of 3–5 years. For Pari-
etaria judaica extracts a monthly maintenance dose equiv-
alent to at least 0.48 µg of Par j1 was achieved. For house
dust mites a monthly maintenance dose equivalent to at
least 3.2 µg of Der 1 and 1.6 µg of Der 2 was reached.
Statistical analyses
The data were analyzed with SAS-PC statistical package
(SAS Institute, Cary, NC). The general characteristics of
the study cases were described with summary statistics
using frequency tables and Chi-square test. Logistic regres-
sion analysis was used to estimate unadjusted and
adjusted odds ratios, significance levels, and confidence
intervals for each study factor associated with asthma
development. The adjusted models included all the other
variables excluding IT treatment, since all those without
rhinitis were not relevant to this variable. Patients on IT
were either treated with Parietaria allergen or mites aller-
gen and never included twice in the statistical calculation.
The variables included in the models were: diagnosis of
rhinitis at the time of the start of the study, sex, family his-
tory of allergy, pet ownership before the age of 5 years,
sensitisation to a number of specific allergens, and paren-
tal smoking at home before the age of 5 years. Changes in
the clinical rating of rhinitic symptoms at follow-up was
separately assessed among rhinitis patients.
In order to better understand how many cases of hay fever
would have to be treated with allergen IT to avert one case
of asthma, the number needed to treat (NNT) was calcu-
lated.
For the analyses, 95% confidence intervals were used and
p values <0.05 were considered significant. Stepwise
regression analysis was carried out and only the statisti-
cally significant variables were included in the final
model.
Results
Predictors of new onset asthma in the study population
In our study population of 436 subjects (237 Males; 199
Females) a total of 161 (36.9%) were diagnosed with
asthma in 2000. Table 1 shows the data, as well as per-
Table 2: Odds Ratios for Factors Predicting the Development of 
New Onset Asthma
Model – Univariate
OR (95% CI)
Presence of allergic rhinitis 10.26 4.83–21788
Female sex 2.19 1.48–3.26
Positive family history for allergic disorders 1.74 1.15–2.64
Presence of pets in the home 2.08 1.38–3.13
Parental smoking at home 1.32 0.88–1.97.
Sensitization to Parietaria judaica 4.26 2.78–6.54
Sensitization to house dust mite 1.33 0.85–2.08
Sensitization to Olea europea 1.63 1.1–2.5
Sensitization to grass pollen 1.52 0.83–2.77
Sensitization to orchard 1.43 0.90–2.25
Sensitization to perennial rye 1.25 0.79–1.98
Sensitization to cats 1.38 0.68–2.81
Treatment with allergen immunotherapy 0.63 0.40–0.98
Model – Multivariate* (significant factors only)
Presence of allergic rhinitis 7.81 3.05–20.04
Female sex 2.83 1.79–4.49
Presence of pets in the home 2.02 1.27–3.21
Sensitization to Parietaria judaica 2.01 1.16–3.47
Treatment with allergen immunotherapy** 0.53 0.32–0.86
*Model included: Allergic rhinitis diagnosis, gender, parental smoking 
at home, family history of allergic diseases, presence of pets at home, 
sensitization to Olea europea, sensitization to house dust mite, 
sensitization to grass pollen, sensitization to orchard, sensitization to 
perennial rye, sensitization to cats, sensitization to Parietaria judaica 
** Model included: immunotherapy history and all the above 
covariates, excluding allergic rhinitis diagnosis.Respiratory Research 2005, 6:153 http://respiratory-research.com/content/6/1/153
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centages for each variable at baseline in addition to the
frequency, according to the diagnosis of asthma at the end
of follow up. Asthmatics were more likely to have had a
higher percentage of rhinitis, family history of allergic dis-
eases, pets in the home, and sensitization to Olea europea
and Parietaria judaica, all of which were statistically signif-
icant. In addition, more asthmatics were females com-
pared to non-asthmatics. All other factors were generally
higher among asthmatics compared to non-asthmatics
although this did not reach statistical significance (Table
1).
We found that 46.1% (n = 153) of those with rhinitis at
baseline developed asthma at the end of follow up while
only 7.7% (n = 8) of the non-allergic subjects at baseline
developed asthma at the end of follow up. Severity and
type of asthma have been subsequently graded according
to GINA guidelines [29]. Among the 153 rhinitic subjects
who were diagnosed with asthma in 2000, 46 (30%) had
intermittent asthma, 91 (59.5%) had mild persistent
asthma, 13 (8.5%) had moderate persistent asthma, and
3 (2.0%) had severe persistent asthma. All the non-aller-
gic subjects with asthma at follow-up (n= 8) had mild per-
sistent asthma.
Among subjects with allergic rhinitis, usage of nasal corti-
costeroids was similar at the end of follow up among the
group with a diagnosis of asthma (n = 80; 52.3%) and the
group who had no symptoms of asthma (n = 85; 47.5%).
Presence of allergic rhinitis at the start of the study was
highly predictive of development of new onset asthma
after 10 years (OR, 10.3; 95%CI, 4.8–21.8) (Table 2). In
the univariate analyses, the second highest OR was for
family history of allergic diseases (OR 4.26 (95% CI 2.78–
6.54). Variables of female gender, presence of pets, and
sensitisation to Olea europea and Parietaria judaica were
significantly predictive of asthma diagnosis at the end of
follow up (Table 2).
Disease duration was not predictive of new incident cases
of asthma in this cohort. Those who had had rhinitis for
>10 years had a non-significant OR of 1.06 (95%CI, 0.62–
1.81) of developing asthma compared to those with dis-
ease duration 2-to-5 years. Likewise, those with 5-to-10
years of rhinitis had a non-significant OR of 1.30 (95%CI,
0.78–2.18) of developing asthma compared to those with
a disease duration of 2-to-5 years. This observed lack of
association was confirmed after adjusting for all other var-
iables in the multivariate model (data not shown).
In the multivariate analyses, adjusting for all other covari-
ates and using the stepwise regression analyses, the same
factors as above were consistently predictive of the diag-
nosis of asthma, excluding Olea europea, which became
non-significant (Table 2). None of the other allergens
tested showed statistically significant associations with
new onset asthma.
Among those who were diagnosed with rhinitis in 1990–
1991, patients who underwent immunotherapy were
more likely to report their rhinitis symptoms improving,
compared to those who did not have the therapy, in a
model adjusted for sex (OR 1.75; 95% CI, 1.11–2.77).
Furthermore, those who reported in 2000 that their rhin-
itis symptoms became better were less likely to develop
asthma compared to those who reported either worsening
or no change in the symptoms (OR 0.33; 95% CI, 0.20–
0.56). This relationship was consistent in the models that
included immunotherapy and other risk factors in the
model.
Effect of allergen immunotherapy on new onset asthma
Out of the 332 allergic rhinitis subjects who were consid-
ered for analysis in the study, 202 subjects underwent
allergen immunotherapy for at least 3 consecutive years
(60.8%). Nineteen subjects had been treated with immu-
notherapy for less than 3 years and were not included in
the treatment group. Usage of nasal corticosteroids was
similar in both the group that used allergen immuno-
therapy (n = 98; 48.5%) and the group that did not (n =
67; 51.5%).
The present data show that 53.1% (n = 69) of subjects
with allergic rhinitis who were not treated with allergen
immunotherapy developed asthma at the end of follow
up, while only 41.6% (n = 84) of subjects with allergic
rhinitis who took allergen immunotherapy were diag-
Percentage of new onset asthma by the end of the study in  allergen immunotherapy (SIT) treated (closed bar) and  untreated (open bar) subjects with allergic rhinitis Figure 3
Percentage of new onset asthma by the end of the study in 
allergen immunotherapy (SIT) treated (closed bar) and 
untreated (open bar) subjects with allergic rhinitis.Respiratory Research 2005, 6:153 http://respiratory-research.com/content/6/1/153
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nosed with asthma (Figure 3). Our study shows that there
was a significant 12% reduction in the prevalence of phy-
sician-diagnosed asthma in adults with allergic rhinitis
with a number needed to treat (NNT) of 8.7. This relation-
ship between immunotherapy and the incidence of
asthma was still observed when the duration of rhinitis
was included in the model (data not shown).
Out of the 232 allergic rhinitis subjects with a positive
skin prick test for Parietaria, specific immunotherapy for
at least 3 consecutive years was administered to 149 sub-
jects (64.2%). Of the allergic rhinitis subjects with a posi-
tive skin prick test for HDM, 64 out of 107 (59.8%)
received specific immunotherapy for at least 3 consecutive
years. Out of the 53 subjects with a co sensitivity towards
Parietaria  and HDM, 38 received Parietaria  immuno-
therapy and 15 were treated with HDM immunotherapy.
Thus patients on immunotherapy were either treated with
Parietaria allergen or mites allergen alone.
The present data show that 61.5% (n = 51 out of 83) of
positive Parietaria subjects with allergic rhinitis but who
were not treated with Parietaria  immunotherapy devel-
oped asthma at the end of follow up while only 46.3% (n
= 69 out of 149) of subjects with allergic rhinitis who took
Parietaria immunotherapy were diagnosed with asthma
(Figure 4) (Chisq = 4.89, p = 0.027). The NNT for this sub-
group was 6.6. In contrast, 48.8% (n = 21 out of 43) of pos-
itive HDM subjects with allergic rhinitis who were not
treated with HDM immunotherapy developed asthma at
the end of follow up, while only 37.5% (n = 24 out of 64)
of subjects with allergic rhinitis who received specific
immunotherapy were diagnosed with asthma (Figure 5)
(Chisq = 1.35, p = 0.24). The NNT for this subgroup was
8.8.
In the univariate analyses, treatment with allergen immu-
notherapy during follow up was inversely related to devel-
opment of asthma after 10 years (OR, 0.63; 95%CI, 0.40–
0.98) (Table 2). This association became stronger after
adjusting for all other variables in the multivariate model
(Table 2). When carrying out univariate analyses for the
relationship between immunotherapy and asthma among
those with Parietaria positive skin prick testing the OR was
0.54 (95% CI 0.31–0.94), whereas for those with HDM
positive skin prick testing the OR was 0.63 (0.29–1.38),
but was not significant statistically.
Discussion
In this retrospective cohort study we found that allergic
rhinitis is strongly predictive of the development of
asthma even after adjustment for other risk factors for
asthma. Other significant risk factors for the development
of asthma were female sex, pet ownership, and family his-
tory of allergic diseases. With the exception of Parietaria
judaica, sensitization to the allergens tested did not predict
long-term asthma diagnosis. In addition, we have shown
for the first time that treatment with allergen immuno-
therapy decreases the incidence of asthma in adults with
allergic rhinitis.
The effect of rhinitis on the onset of asthma has been
already investigated in longitudinal studies. Huovinen et
al. [17] found that hay fever increased the risk of develop-
ment of asthma during a 15-year follow-up period by 4
times among adult men and by 6 times among women.
However, no information on atopic status was available.
Similarly, in the cohort of Brown University freshmen
[14] both allergic rhinitis and positive skin test responses
increased the risk of development of asthma by about 3
times. This is in support of our findings, although the risk
from our data was much higher. Data from large popula-
tion-based studies clearly show that rhinitis is a risk factor
for asthma among subjects with negative, as well as posi-
tive, skin test responses thus suggesting that rhinitis and
asthma are not associated simply because they share atopy
as a common risk factor [15,16,18,30].
In this study, some of the factors that have been normally
considered important risk factors for the development of
asthma were examined. As one would predict, the female
sex, the presence of pets in the home and a positive family
history of allergic diseases were all predictive of new onset
asthma in our study population of Sicilians. Our findings
Percentage of new onset asthma by the end of the study in  Parietaria immunotherapy (SIT) treated (clear pointed bar)  and untreated (dark pointed bar) allergic rhinitic subjects  with positive skin prick test to Parietaria Figure 4
Percentage of new onset asthma by the end of the study in 
Parietaria immunotherapy (SIT) treated (clear pointed bar) 
and untreated (dark pointed bar) allergic rhinitic subjects 
with positive skin prick test to Parietaria.Respiratory Research 2005, 6:153 http://respiratory-research.com/content/6/1/153
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are in agreement with the results from most studies of
adults showing that asthma is more prevalent in women
than in men [31,32] and that family history of allergy is
consistently identified as an important risk factor for
asthma [33]. In keeping with the role of indoor allergens
from domestic animals as an important risk factor for
asthma and asthma-related symptoms [34,35], we have
shown that the presence of pets in the home was signifi-
cantly predictive of new onset asthma in individuals with
allergic rhinitis.
Sensitization to allergen has been shown to be one of the
strongest determinants of asthma, and individuals with a
predisposition for atopy are at higher risk [36]. Of all
known common allergens, the house dust mite is known
to be strongly implicated as a potential cause of asthma
[37,38]. However, in this population of Sicilians, house
dust mite sensitization was not significantly predictive of
new onset asthma. Instead, we have been able to show for
the first time that (of all allergens tested) positive sensiti-
zation to Parietaria judaica markedly increased the risk of
developing asthma. The reasons for this discrepant result
are not known, but are probably related to the peculiar
characteristics of the inhalant allergen type. The Parietaria
pollen is widespread in the Mediterranean area with a very
high frequency of sensitization (up to 80% in Sicily) and
its long persistence in the atmosphere (Parietaria pollen
season in Sicily ranges from February to October) is often
responsible for most perennial symptoms [39]. In con-
trast to mite allergens, Parietaria pollen has very strong
allergenic properties and often reaches very high peak lev-
els during its season [39,40].
It is unclear why a large proportion of individuals with
atopy and rhinitis eventually progress to bronchial
asthma. Although atopy per se carries an increased risk for
subsequent development of asthma in rhinitic individu-
als, it is likely that chronic exposure to airborne allergens
is important. In our study population, up to 70% of rhi-
nitic subjects were allergic to Parietaria pollen. In Sicily,
Parietaria-sensitive subjects with allergic rhinitis are likely
to be exposed to very high allergen levels, and this high
allergenic load may promote progression to bronchial
inflammation and asthma. The findings of our recent
work in non-asthmatic subjects with allergic rhinitis mon-
osensitized to Parietaria judaica shows a substantial
increase in non-invasive surrogate markers of bronchial
inflammation during periods of seasonal exposure to Pari-
etaria pollen [41], thus suggesting that ongoing exposure
to Parietaria pollen is closely associated with inflamma-
tory changes in the bronchial airways of subjects with
allergic rhinitis, that may advance to clinical asthma.
Another significant finding of the present study is that
treatment with allergen immunotherapy reduces the
development of asthma in adults with allergic rhinitis.
This association has been investigated here for the first
time among adults. In support of our findings, clinical
research studies have suggested that when allergen immu-
notherapy is introduced to individuals with allergic rhino-
conjunctivitis, the development of asthma may be halted.
The pioneering study of Johnstone and Dutton [42]
showed that 28% of children receiving allergen vaccina-
tion developed asthma in compared to 78% of placebo-
treated children. The Preventive Allergy Treatment (PAT)
study in children with grass or birch pollen rhino-con-
junctivitis [21] has been instrumental in providing
encouraging evidence to support the notion that specific
allergen immunotherapy may stop the development of
asthma. From six paediatric allergy centres in Austria,
Denmark, Finland, Germany and Sweden, 205 children
with moderate to severe hay fever symptoms were ran-
domly assigned either to receive immunotherapy for 3
years, or to an open control group. By the end of the study,
the actively treated children developed significantly fewer
asthma symptoms. However, in children, wheezing and
coughing from non-asthmatic respiratory illness can
mimic asthma. The results from the 6 centres were not
consistent and there were a small number of children in
each centre. Furthermore, 20% of the study population
were diagnosed with asthma at baseline and apparently
were not excluded. In a recent randomized, placebo-con-
trolled 3-year study of allergen immunotherapy in non-
asthmatic, rhinitic adults monosensitized to Parietaria
pollen, we reported that 47% of patients in the placebo
Percentage of new onset asthma by the end of the study in  HDM immunotherapy (SIT) treated (clear hatched bar) and  untreated (dark hatched bar) allergic rhinitic subjects with  positive skin prick test to HDM Figure 5
Percentage of new onset asthma by the end of the study in 
HDM immunotherapy (SIT) treated (clear hatched bar) and 
untreated (dark hatched bar) allergic rhinitic subjects with 
positive skin prick test to HDM.Respiratory Research 2005, 6:153 http://respiratory-research.com/content/6/1/153
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group developed asthma symptoms by the end of the
study, as opposed to only 14% of those treated with
immunotherapy [23]. However, the small sample size (n
= 29), including only those sensitized to Parietaria, lim-
ited our power to detect a statistically significant change
between the two groups.
The observed effect of allergen IT in reducing the onset of
new asthma cases is of clinical importance. Our study
shows that there was a significant 12% reduction in the
prevalence of physician-diagnosed asthma in adults with
allergic rhinitis, with a number needed to treat (NNT) of
8.7; which is better than that of 10 obtained in the recent
Childhood Asthma Prevention Study with omega-3 fatty
acid supplementation and house dust mite allergen avoid-
ance [43]. To our knowledge there is no other asthma pre-
vention study that can exhibit a greater effect. Moreover,
Parietaria  immunotherapy appears to reduce develop-
ment of asthma even further. Considering the high preva-
lence of Parietaria  sensitivities in our area and the
importance of positive sensitization to Parietaria  as a
major independent risk factor for the development of
asthma in this study population, we did secondary analy-
sis for the effects of allergen specific immunotherapy
among those individuals with positive sensitivity to Parie-
taria  and those with positive sensitivity to HDM. This
analysis clearly shows that treatment with Parietaria
immunotherapy reduces development of asthma in adults
with allergic rhinitis, with a calculated NNT of 6.6. In con-
trast, treating positive HDM subjects with allergic rhinitis
with HDM immunotherapy failed to reduce the rising
incidence of asthma in this subgroup. The observed dis-
parity in responses to different allergen extracts for IT in
the present study may provide an additional explanation
for the inconsistency in the results from the 6 centres in
the PAT-study [21].
Our study has the advantage of a relatively long follow up
period of 10 years. The cohort approach minimizes the
possibility of reverse causality that may be encountered in
case-control studies, where it is not possible to know if the
asthma began after or before the exposure, or in this case
allergic rhinitis. Another advantage of this study is the rig-
orous clinical assessment of asthma diagnosis prior to
exclusion at baseline and for its diagnosis as an outcome
at the end of follow up. Failing to diagnose actual asthma
cases at baseline would have introduced systematic bias,
which could affect the results by either increasing or
decreasing the observed OR. On the other hand, missing
the diagnosis of asthma at the end of follow up would
have attenuated the observed OR. Even with all the instru-
ments and expertise available for this study, we had to
exclude 39 cases because asthma diagnosis was unclear.
The fact that the study subjects were examined by the
same respiratory unit at baseline and at follow up 10 years
afterwards is important for standardising asthma diagno-
sis criteria in such a population.
It is also important to obtain an accurate history of steroid
and other asthma treatments during follow up. As intrana-
sal use of corticosteroids [44,45] has been shown to
reduce asthma symptoms in patients with allergic rhinitis,
we attempted to address these variables in our cohort and
there was no difference between asthmatics and non-asth-
matics for these treatments. This may explain the higher
OR in our study compared to earlier studies.
A possible weakness of our study includes relying on med-
ical records for the selection of the study subjects at base-
line. However, all these subjects were examined and
carefully diagnosed and documented in the clinic by our
specialists. The lower response rate due to the change in
the telephone numbers during follow up might have
affected our results. However, we do not expect that this
lower response is related to the diagnosis of asthma and
therefore any random error introduced by lower participa-
tion is likely to attenuate rather than exaggerate the
observed OR.
In conclusion, our study shows that immunotherapy can
be used to reduce progression to asthma later on, espe-
cially when there are symptoms of allergic rhinitis and
atopy. Allergic rhinitis seems to pose a much higher long-
term risk than previously thought. The main allergy-
related risk for asthma in Siciliy, and possibly other Med-
iterranean countries, seems to be Parietaria pollen rather
than house dust mites. These are important findings for
clinicians to help guide them in the prevention and treat-
ment of their patients. Well conducted clinical trials may
shed more light on the significance of our findings in rela-
tion to the long-term prevention of asthma.
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